Fu Hong Han Lin (02696) achieved adjusted net profit of about 572 million yuan in the first half of the year, a year-on-year increase of 46.71%, and “going overseas” achieved remarkable results

According to the Zhitong Finance App, Fu Hong Han Lin (02696) announced the 2026 interim results, with total revenue of about 3,588 billion yuan, an increase of about 27.3% over the previous year. R&D expenditure was about 1,451 billion yuan, up 45.74% year on year; total profit was about 430 million yuan, up 10.33% year on year; non-IFRS profit was about 572 million yuan, up 46.71% year on year. Among them, global product sales revenue (including revenue from product supply and royalties based on sales) was approximately $2,9386 million, an increase of about 14.9% over the previous year.

According to the announcement, the increase in R&D expenditure is mainly used to increase investment in innovative R&D projects to accelerate the Group's innovation and transformation. Among them, the cost of R&D expenses was about 826 million yuan, an increase of 41.08% over the previous year.

The increase in profit was mainly due to the continued commercialization of core products, a sharp increase in overseas commercial profits, and the expansion of clinical R&D activities. During the period, overseas product sales revenue (including overseas product supply revenue and royalty revenue based on sales) was about 105 million yuan, and overseas product profit (including gross profit from overseas product supply and royalty profit based on sales) was about 59.5 million yuan. Compared with the same period last year, it achieved a breakthrough increase of more than 4 times compared to the same period last year, mainly due to the Group's adherence to an internationalization strategy and sales volume in the US market, which helped the international profit level continue to rise.

As of the last practical date, the Group's 10 products (41 indications) have been successfully approved for listing in countries/regions such as China, the United States, Europe, Canada, Australia, Brazil, South Korea, Indonesia, and the Dominican Republic; 7 of these products have been approved for listing in different overseas markets, covering more than 60 countries/regions, benefiting more than 1.1 million patients worldwide.

Adhering to the internationalization strategy, the group reached a number of new collaborations with well-known international companies during the reporting period, and further expanded the internationalization of products. At the same time, the Group has sharpened close cooperation between mature global pharmaceutical administration registration teams, global clinical operations and medical teams to comprehensively advance the development process of pipeline products at home and abroad. During the reporting period, the Group received 32 clinical trial application (IND) approvals and 25 marketing registration application (NDA) approvals, covering nearly 50 countries including China, the United States, Europe, Japan, and Canada; as of the last practical date, the Group's self-built clinical operation teams in China, the United States, Australia and Japan promoted clinical research in an orderly manner in more than 20 countries/regions.